Claims for Patent: 10,898,453

Summary for Patent: 10,898,453

Title:	Bupropion as a modulator of drug activity
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Tabuteau; Herriot (New York, NY)
Assignee:	ANTECIP BIOVENTURES II LLC (New York, NY)
Application Number:	16/894,713
Patent Claims:	1. A method of treating major depressive disorder, comprising: orally administering a combination of a bupropion and a dextromethorphan to a human being suffering from major depressive disorder for at least 21 consecutive days; wherein the combination comprises: a daily dose of about 150 mg to about 250 mg of bupropion hydrochloride, or a molar equivalent amount of the free base or another salt form of bupropion, and a daily dose of about 60 mg to about 100 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base or another salt form of dextromethorphan; wherein the daily doses of the bupropion and the dextromethorphan are orally administered once a day or are a total of twice daily doses, the combination is administered in a single dosage form comprising the bupropion and the dextromethorphan as the only therapeutically active compounds, which provides immediate release of dextromethorphan and sustained release of bupropion; and wherein orally administering the combination of the bupropion and the dextromethorphan is more effective in treating major depressive disorder than orally administering the same dosage regimen of the bupropion without the dextromethorphan. 2. The method of claim 1, wherein about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base or another salt form of dextromethorphan, is orally administered twice a day. 3. The method of claim 1, wherein about 100 mg to about 120 mg of bupropion hydrochloride, or a molar equivalent amount of the free base or another salt form of bupropion, is orally administered twice a day. 4. The method of claim 2, wherein about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base or another salt form of bupropion, is orally administered twice a day. 5. The method of claim 1, wherein about 90 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base or another salt form of dextromethorphan, is orally administered once a day. 6. The method of claim 1, wherein about 200 mg to about 250 mg of bupropion hydrochloride, or a molar equivalent amount of the free base or another salt form of bupropion, is orally administered once a day. 7. The method of claim 1, wherein the combination of the bupropion and the dextromethorphan is orally administered to the human being suffering from major depressive disorder for at least 35 consecutive days. 8. The method of claim 1, wherein the human being is suffering from treatment-resistant major depressive disorder. 9. The method of claim 1, wherein the dextromethorphan and the bupropion are orally administered for at least 6 weeks. 10. The method of claim 1, wherein the dextromethorphan comprises a deuterium-modified dextromethorphan.